Targeting diazo prodrugs for the treatment of gastrointestinal diseases

Abstract

Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient to reduce, alleviate or treat various gastrointestinal diseases, such as inflammatory bowel disease (IBD).

Description

[0001] This application claims the benefit of US Provisional Patent Application 60 / 947,104, filed June 29, 2007, entitled "Targeting Prodrugs for the Treatment of Gastrointestinal Diseases," the disclosure of which is incorporated herein by reference in its entirety. technical field [0002] The present application relates to compounds and pharmaceutical compositions useful in the treatment of gastrointestinal disorders, including but not limited to inflammatory disorders such as inflammatory bowel disease (IBD). Background technique [0003] Drug targeting can be defined as the delivery of a drug to a specific organ, tissue or cell population (Schreier 2001). Still in its nascent stage, this field offers the promise of enhancing the efficacy of drug treatments while reducing systemic effects or side effects. Despite the promise of this approach and ongoing efforts, there have been few successes to date, partly due to limited understanding of the fundamentals of drug deliver...

AI Technical Summary

Problems solved by technology

Although some of these designs are promising, they have met with limited success to date, partly due to the widespread distribution of glycosidases in the gastrointestinal tract (resulting in non-site-specific release; Sinha & Kumria, 2001), and in some cases lower, due to the slow release profile in the colon (up to 12h for some polysaccharides, Yang; 2002)

Images